Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy
Shutong Li, Aoxue Wang, Yongya Wu, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 300-334
Closed Access | Times Cited: 18

Showing 18 citing articles:

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Fei Ren, Qian Fei, Kun Qiu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 27
Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
Jin Zhang, Yue Ma
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116909-116909
Open Access | Times Cited: 8
CircKIAA0182 Enhances Lung Cancer Progression and Chemoresistance through Interaction with YBX1
Masha Huang, Jingyi Sun, Qingqing Jiang, et al.
Cancer Letters (2025) Vol. 612, pp. 217494-217494
Closed Access
GTPase GPN3 facilitates cell proliferation and migration in non-small cell lung cancer by impeding clathrin-mediated endocytosis of EGFR
Linlin Xu, Jiankun Guo, Xinsheng Xie, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Human Embryonic Kidney HEK293 Cells as a Model to Study SMVT-Independent Transport of Biotin and Biotin-Furnished Nanoparticles in Targeted Therapy
Magdalena Twardowska, Andrzej Łyskowski, Maria Misiorek, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1594-1594
Open Access
Therapeutic Potential of Biotoxins and Biotechnological Innovations
Prince Kumar Singh, Gereraj Sen Gupta, Indrajeet Kumar, et al.
(2025), pp. 381-410
Closed Access
NSUN4 Facilitates the Activity of Oncogenic Protein CDC20 to Promote NSCLC Development by Mediating m5C Modification of CDC20 mRNA
Zhilong Li, Wu Xianzhen
Thoracic Cancer (2025) Vol. 16, Iss. 5
Open Access
Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression
Sijie Liu, Xun Wu, Yanjie Wang, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 4
Closed Access | Times Cited: 4
Inducing ferroptosis by traditional medicines: a novel approach to reverse chemoresistance in lung cancer
Yumin Wang, Jing Hu, Joshua S. Fleishman, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Inhibiting autophagy enhanced mitotic catastrophe-mediated anticancer immune responses by regulating the cGAS-STING pathway
Zhaoshi Bai, Yaling Peng, Xue'er Xia, et al.
Cancer Letters (2024) Vol. 586, pp. 216695-216695
Closed Access | Times Cited: 2
Pan-cell death-related signature reveals tumor immune microenvironment and optimizes personalized therapy alternations in lung adenocarcinoma
Linzhi Han, Jingyi He, Hongxin Xie, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Cepharanthine Triggers Ferroptosis Through Inhibition of NRF2 For Robust ER Stress Against Lung Cancer
Xiaofeng Bai, Jun Hu, Meifang Wang, et al.
European Journal of Pharmacology (2024) Vol. 979, pp. 176839-176839
Closed Access | Times Cited: 2
Cell type‐specific molecular mechanisms and implications of necroptosis in inflammatory respiratory diseases
Ying Guo, Jin Zhou, Yaqi Wang, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 52-70
Closed Access | Times Cited: 3
Mechanisms of programmed cell death
Tian Li, Guido Kroemer
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 5-6
Open Access | Times Cited: 3
One Case of Immunotherapy for Non-Small Cell Lung Cancer
登 潘
Advances in Clinical Medicine (2024) Vol. 14, Iss. 08, pp. 1304-1310
Closed Access
SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1
Jiawei Chen, Kebin Chen, Shuai Zhang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Integrated machine learning survival framework to decipher diverse cell death patterns for predicting prognosis in lung adenocarcinoma
Fangchao Zhao, Xu Zhang, Yanhua Tian, et al.
Genes and Immunity (2024) Vol. 25, Iss. 5, pp. 409-422
Closed Access
Codonopsis pilosula polysaccharide suppresses the progression of non-small cell lung cancer by triggering NLRP3/GSDMD-dependent pyroptosis
Shaoyan Huang, Quanxing Li, Yaobo Song
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Efficacy and safety of combining radiotherapy with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a real-world study
Guanli Yang, Zhen Zhou, Chengxin Liu
Immunopharmacology and Immunotoxicology (2024) Vol. 46, Iss. 6, pp. 861-871
Open Access
Page 1

Scroll to top